Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: A randomized controlled trial-Reference-Cited by-同舟云学术

Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: A randomized controlled trial

Published:2014-09 Issue:9 Volume:24 Page:1475-1482
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Ahmed Amir I.A.,van den Elsen Geke A.H.,Colbers Angela,van der Marck Marjolein A.,Burger David M.,Feuth Ton B.,Rikkert Marcel G.M. Olde,Kramers Cornelis

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology

Reference29 articles.

1. Medicinal use of cannabis and cannabinoids in older adults: where is the evidence?;Ahmed;J. Am. Geriatr. Soc.,2014

2. Pharmacology and effects of cannabis: a brief review;Ashton;Br. J. Psychiatry,2001

3. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities;Bosier;Biochem. Pharmacol.,2010

4. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations;Bowdle;Anesthesiology,1998

5. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study;Carroll;Neurology,2004

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cannabis Use and Cognitive Functioning Across the Lifespan;Current Addiction Reports;2024-04-15

2. CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions;Pharmaceutics;2024-04-01

3. MODULAÇÃO DE CRISES EPILÉTICAS EM CANINO COM MENINGOENCEFALITE GRANULOMATOSA UTILIZANDO FITOCANABINÓIDES: RELATO DE CASO;Revista Contemporânea;2024-03-14

4. Effects of Chronic, Low-Dose Cannabinoids, Cannabidiol, Delta-9-Tetrahydrocannabinol and a Combination of Both, on Amyloid Pathology in the 5xFAD Mouse Model of Alzheimer's Disease;Cannabis and Cannabinoid Research;2023-10-20

5. Measuring the diversity gap of cannabis clinical trial participants compared to people who report using cannabis;Scientific Reports;2023-06-16